Toprol OK's a boon for Watson amid shortage

Watson Pharmaceuticals could reap big benefits from the approval of its version of the blood pressure med Toprol XL, because two rival generic drugs were suspended because of manufacturing problems. "We get these opportunities every once in a while and this is one of those unique opportunities," Watson spokeswoman Patty Eisenhaur told Reuters, referring to the sudden recent disappearance from the U.S. market of the rival Novartis and KV Pharmaceutical generics. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.